At stage-III colorectal cancer patients, decisions for adjuvant treatment are weighed against possible side effects in patients with important comorbidity and the analysis of IDO1 expression at the tumour invasion front was suggested to be of additional value in the decision process [42]. This evidence concerns the gene IDO1 and colorectal cancer.